📰 Hartmutj Ehrlich News
Page 7 - Hartmutj Ehrlich News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hartmutj Ehrlich. Real-time updates on events, politics, business and more.
December 15, 2021
DGAP-News: ABIVAX / Key word(s): Conference15.12.2021 / 18:30 The issuer is solely responsible for the content of this announcement.Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference Abivax's presentation at the virtual J.P. Morgan Healthcare Conference scheduled for Thursday, January 13, 20...
December 1, 2021
End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)PARIS, FRANCE / ACCESSWIRE /
December 1, 2021
Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that... | December 1, 2021
December 1, 2021
DGAP-News: ABIVAX / Key word(s): Study01.12.2021 / 19:30 The issuer is solely responsible for the content of this announcement.Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitisEnd-of-phase-2 response from the US regulatory agency (FDA) provides guidanc...
October 18, 2021
Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacyFavorable safety and tolerability
May 24, 2021
Search jobs 24-May-2021 Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 DGAP-News: ABIVAX / Key word(s): Study results 24.05.2021 / 18:30 The issuer is solely responsible for the content of this announcement. Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 Primary endpoint ...
March 6, 2021
Press release content from Accesswire. The AP news staff was not involved in its creation. Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy March 5, 2021 GMT The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups Decision has no impact ...
March 5, 2021
ABIVAX Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy DGAP-News: ABIVAX / Key word(s): Study Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy 05.03.2021 / 20:00 Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerate...
March 3, 2021
ABIVAX Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal Gastroenterology DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal Gastroenterology 03.03.2021 / 18:30 The issuer is solely responsible for the content of this announcement. Abivax publishes data of ABX464 induction and long-term mainte...
March 1, 2021
Press release content from Accesswire. The AP news staff was not involved in its creation.